Gilead Sciences, Inc.
GILD
$134.94
$1.421.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.96B | 7.92B | 7.77B | 7.08B | 6.67B |
| Total Other Revenue | -- | 1.00M | -- | 1.00M | -- |
| Total Revenue | 6.96B | 7.93B | 7.77B | 7.08B | 6.67B |
| Cost of Revenue | 1.45B | 1.62B | 1.57B | 1.50B | 1.54B |
| Gross Profit | 5.52B | 6.31B | 6.20B | 5.58B | 5.13B |
| SG&A Expenses | 1.43B | 1.78B | 1.35B | 1.36B | 1.22B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.23B | 4.96B | 4.26B | 4.31B | 4.10B |
| Operating Income | 2.73B | 2.96B | 3.51B | 2.77B | 2.57B |
| Income Before Tax | 2.58B | 2.08B | 3.64B | 2.43B | 1.65B |
| Income Tax Expenses | 559.00M | -105.00M | 589.00M | 468.00M | 334.00M |
| Earnings from Continuing Operations | 2.02B | 2.18B | 3.05B | 1.96B | 1.32B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.02B | 2.18B | 3.05B | 1.96B | 1.32B |
| EBIT | 2.73B | 2.96B | 3.51B | 2.77B | 2.57B |
| EBITDA | 3.42B | 3.65B | 4.20B | 3.46B | 3.26B |
| EPS Basic | 1.63 | 1.76 | 2.46 | 1.57 | 1.06 |
| Normalized Basic EPS | 1.30 | 1.41 | 1.68 | 1.30 | 1.21 |
| EPS Diluted | 1.61 | 1.74 | 2.43 | 1.56 | 1.04 |
| Normalized Diluted EPS | 1.29 | 1.40 | 1.67 | 1.29 | 1.19 |
| Average Basic Shares Outstanding | 1.24B | 1.24B | 1.24B | 1.25B | 1.25B |
| Average Diluted Shares Outstanding | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B |
| Dividend Per Share | 0.82 | 0.79 | 0.79 | 0.79 | 0.79 |
| Payout Ratio | 51.46% | 45.53% | 32.93% | 50.71% | 76.81% |